Metformin and breast cancer: Basic knowledge in clinical context

Cancer Treatment Reviews

Volumn 41, Issue 5, 2015, Pages 441-447

  Pizzuti, Laura ^a   Vici, Patrizia ^a   Di Lauro, Luigi ^a   Sergi, Domenico ^a   Della Giulia, Marina ^a   Marchetti, Paolo ^b   Maugeri Saccà, Marcello ^a   Giordano, Antonio ^c,d   Barba, Maddalena ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c Temple University   (United States)

^d UNIVERSITY OF SIENA   (Italy)

Author keywords

Breast cancer; Metformin; Outcome interpretation; Population target

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; GANITUMAB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; KI 67 ANTIGEN; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PLATINUM COMPLEX; PROTEIN P53; SOMATOMEDIN C RECEPTOR; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST METASTASIS; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INTRADUCTAL CARCINOMA; KINESIOTHERAPY; LUMINAL B BREAST CANCER; METABOLIC SYNDROME X; OBESITY; PATIENT SELECTION; POSTMENOPAUSE; PROGRESSION FREE SURVIVAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ANIMAL; BREAST NEOPLASMS; FEMALE;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; METFORMIN;

EID: 84937511328     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2015.03.002     Document Type: Review

References (40)

1. United Kingdom Diabetes study group United Kingdom Prospective Diabetes Study (UKPDS). Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995, 31:83-88.
2. Diamanti-Kandarakis E., Economou F., Palimeri S., Christakou C. Metformin in polycystic ovary syndrome. Ann N Y Acad Sci 2010, 1205:192-198.
3. Bianchi C., Penno G., Romero F., Del Prato S., Miccoli R. Treating the metabolic syndrome. Exp Rev Cardiovasc Ther 2007, 5:491-506.
4. Knowler W.C., Barett-Connor E., Fowler S.E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.
5. Noto H., Goto A., Tsujimoto T., Noda M. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS ONE 2012, 7:e33411.
6. Col N.F., Ochs L., Springmann V., Aragaki A.K., Chlebowski R.T. Metformin and breast cancer risk: a meta-analysis and critical literature review. Breast Cancer Res Treat 2012, 135:639-646.
7. Bonanni B., Puntoni M., Cazzaniga M., et al. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol 2012, 30:2593-2600.
8. Niraula S., Dowling R.J., Ennis M., et al. Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat 2012, 135:821-830.
9. Hadad S., Iwamoto T., Jordan L., et al. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res Treat 2011, 128:783-794.
10. Cazzaniga M., DeCensi A., Pruneri G., et al. The effect of metformin on apoptosis in a breast cancer presurgical trial. Br J Cancer 2013, 109:2792-2797.
11. Campagnoli C., Berrino F., Venturelli E., et al. Metformin decreases circulating androgen and estrogen levels in nondiabetic women with breast cancer. Clin Breast Cancer 2013, 13:433-438.
12. Wahdan-Alaswad R., Fan Z., Edgerton S.M., et al. Glucose promotes breast cancer aggression and reduces metformin efficacy. Cell Cycle 2013, 12:3759-3769.
13. Hadad S.M., Hardie D.G., Appleyard V., Thompson A.M. Effects of metformin on breast cancer cell proliferation, the AMPK pathway and the cell cycle. Clin Transl Oncol 2014, 16:746-752.
14. Zordoky B.N., Bark D., Soltys C.L., Sung M.M., Dyck J.R. The anti-proliferative effect of metformin in triple-negative MDA-MB-231 breast cancer cells is highly dependent on glucose concentration: implications for cancer therapy and prevention. Biochim Biophys Acta 2014, 1840:1943-1957.
15. Hirsch H.A., Iliopoulos D., Struhl K. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc Natl Acad Sci USA 2013, 110:972-977.
16. Lega I., Shah P., Margel D., Beyene J., Rochon P.A., Lipscombe L.L. The effect of metformin on mortality following cancer among patients with diabetes. Cancer Epidemiol Biomarkers Prev 2014, 23:1974-1984.
17. last accessed in November 2014 , last accessed in November 2014.18. https://clinicaltrials.gov/.
18. Dowling R.J., Goodwin P.J., Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Med 2011, 9:33.
19. O'Reilly K.E., Rojo F., She Q.B., et al. MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006, 66:1500-1508.
20. Easton J.B., Kurmasheva R.T., Houghton P.J. IRS-1: auditing the effectiveness of mTOR inhibitors. Cancer Cell 2006, 9:153-155.
21. Goodwin P.J., Stambolic V., Lemieux J., et al. Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat 2011, 126:215-220.
22. Dowling R.J., Niraula S., Stambolic V., Goodwin P.J. Metformin in cancer: translational challenges. J Mol Endocrinol 2012, 48:R31-R43.
23. Weber J.D., Gutmann D.H. Deconvoluting mTOR biology. Cell Cycle 2012, 236-248.
24. DeCensi A., Puntoni M., Gandini S., et al. Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial. Breast Cancer Res Treat 2014, 148:81-90.
25. Vici P., Pizzuti L., Natoli C., et al. Triple positive breast cancer: A distinct subtype. Cancer Treat Rev 2014, pii: S0305-7372(14)00210-2.
26. Vici P., Pizzuti L., Natoli C., et al. Outcomes of HER-2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study. Breast Cancer Res Treat 2014, 147:599-607.
27. Inwald E.C., Klinkhammer-Schalke M., Hofstädter F., et al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat 2013, 139:539-552.
28. Luporsi E., André F., Spyratos F., et al. Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat 2012, 132:895-915.
29. Taneja P., Maglic D., Kai F., Zhu S., Kendig R.D., Fry E.A., et al. Classical and novel prognostic markers for breast cancer and their clinical significance. Clin Med Insights Oncol 2010, 20(4):15-34.
30. Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002, 2:594-604.
31. Dobes P., Podhorec J., Coufal O., et al. Influence of mutation type on prognostic and predictive values of TP53 status in primary breast cancer patients. Oncol Rep 2014, 32:1695-1702.
32. Olivier M. The clinical value of somatic TP53 mutations in 1794 patients with breast cancer. Clin Cancer Res 2006, 12:117-1157.
33. Kruse J., Gu W. Modes of p53 regulation. Cell 2009, 137:609-622.
34. Zajkowicz A., Rusin M. The activation of the p53 pathway by the AMP mimetic AICAR is reduced by inhibitors of the ATM or mTOR kinases. Mech Ageing Dev 2011, 132:543-551.
35. Shackelford D.B., Shaw R.J. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 2009, 9:563-575.
36. Wullschleger S., Loewith R., Hall M.N. TOR signaling in growth and metabolism. Cell 2006, 124:471-484.
37. Nieminen A., Eskelinen V., Haikala H., et al. Myc-induced AMPK-phospho p53 pathway activates Bak to sensitize mitochondrial apoptosis. Proc Natl Acad Sci USA 2013, 110(20).
38. Sen N., Satija Y.K., Das S. p53 and metabolism: old player in a new game. Transcription 2012, 3(3):119-123.
39. Barba M., Sperati F., Stranges S., et al. Fasting glucose and treatment outcome in breast and colorectal cancer patients treated with targeted agents: results from a historic cohort. Ann Oncol 2012, 23:1838-1845.
40. Vici P., Sperati F., Maugeri-Saccà M., et al. P53 status as effect modifier of the association between pre-treatment fasting glucose and breast cancer outcomes in non diabetic, HER-2 positive patients treated with trastuzumab. Oncotarget 2014, 5:10382-10392.